Is Novo Nordisk's GLP-1 Dominance Fading After Lilly's Clinical Wins?

Core Insights - Novo Nordisk's shares fell 21% following disappointing clinical results and pricing pressures, erasing gains from the approval of Wegovy in 2021 [1] Competitive Landscape - Eli Lilly has become a significant competitor in the GLP-1 obesity market with its Zepbound, which has been gaining market share due to superior weight-loss efficacy compared to Wegovy [2] - In a recent phase III study, Zepbound achieved a 25.5% weight loss at 84 weeks, outperforming Novo Nordisk's CagriSema, which recorded a 23% weight loss, marking a competitive win for Lilly [3][4] - Eli Lilly's oral GLP-1 candidate, orforglipron, also outperformed Novo Nordisk's Rybelsus in a phase III study, achieving a 2.2% reduction in A1C and 9.2% weight loss at 52 weeks, indicating a stronger competitive position [5][6] Pricing Strategy - Novo Nordisk plans to reduce the U.S. list prices of its major products, including Wegovy, Ozempic, and Rybelsus, to $675 per month starting January 2027, aiming to improve patient access but risking margin compression amid rising competition [7] Market Performance - Novo Nordisk's stock has underperformed, losing 34% over the past six months compared to the industry's 24.5% growth [11] - The company's shares are trading at a forward P/E ratio of 11.17, significantly lower than the industry average of 18.70 and below its five-year mean of 29.25 [14] Earnings Estimates - Earnings estimates for Novo Nordisk have declined, with 2026 estimates dropping from $3.54 to $3.36 per share and 2027 estimates from $3.65 to $3.30 [16]